DNA

Thomas Alva Edison accumulated 1,093 US patents over his lifetime. Most R&D operations are not that efficient. Corporations hate research. It is expensive. The scientists know more about a...
These are some of the top pre-market upgrades from Wall Street analysts this Wednesday morning: AmerisourceBergen (ABC) Started as Buy at Jefferies. Broadcom (BRCM) Raised to Outperform at Baird....
According to Reuters, economic attention has now turned to the recession.Reuters reports that a new survey shows that half of all workers are worried about their jobsReuters reports that unions are...
Genentech, Inc. (NYSE: DNA) today posted earnings of $0.81 per share and $3.408 billion in revenue. That’s below First Call estimates of $0.88 on $3.36 billion in revenue.  For what this is worth,...
After today’s close, we are expecting the earnings report of of biotech giant Genentech, Inc. (NYSE: DNA).  First Call estimates are for $0.88 EPS on $3.36 billion in revenue.  Today is going to...
Analysts assume third quarter earnings for the companies in the S&P 500 will be bad. But, looking at the number which is the average of all firms in the index is misleading. The market will be...
OSI Pharmaceuticals Inc. (NASDAQ: OSIP) is getting hit hard in early trading this morning.  The biotech has released data showing that a Phase III trial of Genentech’s (NYSE: DNA) Avastin combined...
These are some of the top upgrades we are seeing from Wall Street analysts this morning: Amgen (AMGN) Raised to Outperform at William Blair. Capital Product Partners (CPLP) Started as Outperform at...
These are some of the early analyst calls we are seeing early this Friday morning: Comverse Technology (CMVT) Cut to Neutral at JPMorgan. Ctrip.com (CTRP) Cut estimates and maintained Buy but target...
According to Reuters, Greenspan says the housing market should bottom in 2009.Reuters writes that US auto makers are scrambling to make more fuel-efficient cars.Reuters reports that the SEC is close...
Genentech Inc. (NYSE: DNA) is running into some issues over the merger with Roche at $89.00 per share.  Wall Street DOES expect this merger to close with Genentech becoming a subsidiary again rather...
Concern about the health of Apple (AAPL) CEO and founder Steve Jobs has been mounting since his appearance to launch the iPhone 3G model. He was terribly thin. Earlier this week, the press raised the...
These are among the top analyst Downgrades or negative analyst calls affecting shares this Monday morning in pre-market trading: Constellation Energy (NYSE: CEG) Downgraded to Underperform at...
Swiss drug company Roche is trying to steal the part of biotech company Genentech (DNA) that it does not already own. Roche has offered to buy the 45% of DNA that belongs to public shareholders for...
According to Reuters, Roche has offered to buy-out Genentech (DNA) for $42.7 billion.Retuers reports that one of Yahoo!’s (YHOO) activist investors has called for a compromise which would put some...